Stockscreener 앱 받기
13.10
0.61%
0.08
전일 마감가:
$13.02
열려 있는:
$12.97
하루 거래량:
989.23K
Relative Volume:
0.79
시가총액:
$662.16M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-3.5501
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
-3.82%
1개월 성능:
+14.61%
6개월 성능:
+10.36%
1년 성능:
+40.48%
1일 변동 폭
$12.82
$13.67
1주일 범위
$12.82
$14.97
52주 변동 폭
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
13.10 | 658.11M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Is KalVista Pharmaceuticals Inc. stock positioned well for digital economyGap Down & High Conviction Buy Zone Picks - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedQuarterly Earnings Summary & AI Powered Buy and Sell Recommendations - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.July 2025 Trends & Consistent Profit Trade Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesQuarterly Portfolio Review & Consistent Growth Equity Picks - newser.com
Citizens reiterates Market Outperform rating on Kalvista stock at $28 target - Investing.com Canada
How to manage a losing position in KalVista Pharmaceuticals Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycle2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - Insider Monkey
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockJuly 2025 Review & Reliable Momentum Entry Alerts - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Millennium Management LLC's Strategic Acquisition in KalVista Ph - GuruFocus
Will KalVista Pharmaceuticals Inc. stock attract more institutional investorsMarket Performance Report & Verified Short-Term Plans - newser.com
Why KalVista Pharmaceuticals Inc. (4XC1) stock is favored by hedge fundsMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Kalvista Pharmaceuticals stock rating maintained as Citizens notes Ekterly launch complexity - Investing.com Australia
Exit strategy if you’re trapped in KalVista Pharmaceuticals Inc.Earnings Recap Report & Daily Volume Surge Signals - newser.com
Is KalVista Pharmaceuticals Inc a good long term investmentTechnology Stock Trends & Low Cost Trading Tips - earlytimes.in
Hereditary Angioedema Market Forecast 2034Competitive - openPR.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q3 2025 Earnings Call Transcript - Insider Monkey
Will a bounce in KalVista Pharmaceuticals Inc. offer an exitMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
Five things for pharma marketers to know for Wednesday, November 12, 2025 - Medical Marketing and Media
KalVista Pharmaceuticals Reports Strong Q3 Results - TipRanks
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):